Cancers is a leading cause of mortality among transplant recipients. The most common cancers are skin tumors. Glioblastoma is the most frequent brain tumor in adults aged 45 - 70 years. It accounts for 12% - 15% of all intracranial tumors. It is characterized by its rapid development and poor prognosis. We report the case of a cerebral glioblastoma in a kidney transplant recipient. Clinical case: Mr G.R, 44 years old caucasian patient who underwent kidney transplantation. Immunosuppressive treatment included cyclosporine, mycophenolate mofetil and methylprednisolone. Creatinine levels after transplantation remained stable at 11 mg/L (96.8 μmol/l) with an estimated glomerular filtration rate (eGFR) of 77 ml/min/1.73m2 after a 15 years of follow-up. A grade IV right fronto-callossal cerebral glioblastoma was diagnosed in our patient. EBV PCR was negative. Therefore, he underwent 25 sessions of radiotherapy combined with oral chemotherapy using temozolomide. One month later, the patient died due to cerebral edema with subfalcine herniation. Conclusion: This is a case of cerebral glioblastoma in a kidney transplant recipient, a population considered at risk for tumor development due to immunosuppressive treatment. This emphasizes the need for a lifelong surveillance and, more importantly a better balance between graft function preservation and the risks associated with immunosuppressants.
References
[1]
Kasiske, B.L., Snyder, J.J., Gilbertson, D.T., et al. (2004) Cancer after Kidney Transplantation in the United States. American Journal of Transplantation, 4, 905-913. https://doi.org/10.1111/j.1600-6143.2004.00450.x
[2]
Mourad, G., Serre, J.-E., Alméras, C., et al. (2016) Complications Infectieuses et néoplasiques après transplantation rénale. Néphrologie & Thérapeutique, 12, 468-487. https://doi.org/10.1016/j.nephro.2016.06.003
[3]
Stupp, R., Brada, M., van den Bent, M.J., et al. (2014) High-Grade Glioma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 25, iii93-iii101. https://doi.org/10.1093/annonc/mdu050
[4]
Davis, M.E. (2016) Glioblastoma: Overview of Disease and Treatment. Clinical Journal of Oncology Nursing, 20, S2-S8. https://doi.org/10.1188/16.CJON.S1.2-8
[5]
Stupp, R., Mason, W.P., van den Bent, M.J., Weller, M., Fisher, B., Taphoorn, M.J.B., Belanger, K., Brandes, A.A., Marosi, C., Bogdahn, U., et al. (2005) Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. The New England Journal of Medicine, 352, 987-996. https://doi.org/10.1056/NEJMoa043330
[6]
Ilham, S., Willis, C., Kim, K., Chung, K.C., Wood, B.M., Tan, M.S., et al. (2023) Cancer Incidence in Immunocompromised Patients: A Single-Center Cohort Study. BMC Cancer, 23, Article No. 33. https://doi.org/10.1186/s12885-022-10497-4
[7]
Khadka, S., Druffner, S.R., Duncan, B.C. and Busada, J.T. (2023) Glucocorticoid Regulation of Cancer Development and Progression. Frontiers in Endocrinology (Lausanne), 14, Article ID: 1161768. https://doi.org/10.3389/fendo.2023.1161768
[8]
Thaunat, O. and Morelon, E. (2005) Cancer and Immunosuppression: Pro- and Antitumoral Effects of Immunosuppressive Drugs. Néphrologie & Thérapeutique, 1, 23-30. https://doi.org/10.1016/j.nephro.2005.01.003
[9]
Beatty, P.R., Krams, S.M., Esquivel, C.O. and Martinez, O.M. (1998) Effect of Cyclosporine and Tacrolimus on the Growth of Epstein-Barr Virus-Transformed B-Cell Lines. Transplantation, 65, 1248-1255. https://doi.org/10.1097/00007890-199805150-00017
[10]
Koehl, G.E., Wagner, F., Stoeltzing, O., et al. (2007) Mycophenolate Mofetil Inhibits Tumor Growth and Angiogenesis in Vitro but Has Variable Antitumor Effects in Vivo, Possibly Related to Bioavailability. Transplantation, 83, 607-614. https://doi.org/10.1097/01.tp.0000253756.69243.65
[11]
Kleine-Döpke, D., Oelke, M., Schwarz, A., Schwager, Y., Lehner, F., Klempnauer, J., et al. (2018) Renal Cell Cancer after Kidney Transplantation. Langenbeck’s Archives of Surgery, 403, 631-641. https://doi.org/10.1007/s00423-018-1694-x
[12]
Dumortier, J. (2009) Effet antitumoral des inhibiteurs du signal de prolifération. Gastroentérologie Clinique et Biologique, 33, S263-S267. https://www.sciencedirect.com/science/article/abs/pii/S0399832009731641 https://doi.org/10.1016/S0399-8320(09)73164-1
[13]
Schaff, L.R. and Mellinghoff, I.K. (2023) Glioblastoma and Other Primary Brain Malignancies in Adults: A Review. JAMA, 329, 574-587. https://doi.org/10.1001/jama.2023.0023
[14]
Westphal, M., Hilt, D.C., Bortey, E., Delavault, P., Olivares, R., Warnke, P.C., Whittle, I.R., Jääskeläinen, J. and Ram, Z. (2003) A Phase 3 Trial of Local Chemotherapy with Biodegradable Carmustine (BCNU) Wafers (Gliadel Wafers) in Patients with Primary Malignant Glioma. Neuro-Oncology, 5, 79-88. https://doi.org/10.1093/neuonc/5.2.79
[15]
Kreisl, T.N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M., Butman, J.A., Camphausen, K., et al. (2009) Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab plus Irinotecan at Tumor Progression in Recurrent Glioblastoma. Journal of Clinical Oncology, 27, 740-745. https://doi.org/10.1200/JCO.2008.16.3055
[16]
Chinot, O.L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., Carpentier, A.F., Hoang-Xuan, K., Kavan, P., Cernea, D., et al. (2014) Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma. The New England Journal of Medicine, 370, 709-722. https://doi.org/10.1056/NEJMoa1308345
[17]
Stupp, R., Taillibert, S., Kanner, A.A., Kesari, S., Steinberg, D.M., Toms, S.A., Taylor, L.P., Lieberman, F., Silvani, A., Fink, K.L., et al. (2015) Maintenance Therapy with Tumor-Treating Fields plus Temozolomide vs Temozolomide Alone for Glioblastomaa: A Randomized Clinical Trial. JAMA, 314, 2535-2543. https://doi.org/10.1001/jama.2015.16669
[18]
Kitange, G.J., Carlson, B.L., Schroeder, M.A., Grogan, P.T., Lamont, J.D., Decker, P.A., Wu, W., James, C.D. and Sarkaria, J.N. (2009) Induction of MGMT Expression Is Associated with Temozolomide Resistance in Glioblastoma Xenografts. Neuro-Oncology, 11, 281-291. https://doi.org/10.1215/15228517-2008-090
[19]
Shinsato, Y., Furukawa, T. and Yunoue, S. (2013) Reduction of mlh1 and pms2 Confers Temozolomide Resistance and Is Associated with Recurrence of Glioblastoma. Oncotarget, 4, 2261-2270. https://doi.org/10.18632/oncotarget.1302
[20]
Stark, A.M., Doukas, A., Hugo, H.-H., Hedderich, J., Hattermann, K., Mehdorn, H.M. and Held-Feindt, J. (2014) Expression of DNA Mismatch Repair Proteins MLH1, MSH2, and MSH6 in Recurrent Glioblastoma. Neurological Research, 37, 95-105. https://doi.org/10.1179/1743132814Y.0000000409
[21]
Desjardins, A., Gromeier, M., Ii, J.E.H., Beaubier, N., Bolognesi, D.P., Friedman, A.H., Friedman, H.S., McSherry, F., Muscat, A., Nair, S., et al. (2018) Recurrent Glioblastoma Treated with Recombinant Poliovirus. The New England Journal of Medicine, 379, 150-161. https://doi.org/10.1056/NEJMoa1716435
[22]
Weller, M., Butowski, N., Tran, D.D., Recht, L.D., Lim, M., Hirte, H., Ashby, L., Mechtler, L., A Goldlust, S., Iwamoto, F., et al. (2017) Rindopepimut with Temozolomide for Patients with Newly Diagnosed, EGFRvIII-Expressing Glioblastoma (ACT IV): A Randomised, Double-Blind, International Phase 3 Trial. The Lancet Oncology, 18, 1373-1385. https://doi.org/10.1016/S1470-2045(17)30517-X
[23]
Liau, L.M., Ashkan, K. and Tran, D.D. (2018) First Results on Survival from a Large Phase 3 Clinical Trial of an Autologous Dendritic Cell Vaccine in Newly Diagnosed Glioblastoma. Journal of Translational Medicine, 16, Article No. 142.
[24]
Acuna, S.A., Huang, J.W., Scott, A.L., Micic, S., Daly, C., Brezden-Masley, C., et al. (2017) Cancer Screening Recommendations for Solid Organ Transplant Recipients: A Systematic Review of Clinical Practice Guidelines. American Journal of Transplantation, 17, 103-114. https://doi.org/10.1111/ajt.13978
